Tasly Pharmaceutical Group Co Ltd
SSE:600535
Tasly Pharmaceutical Group Co Ltd
SSE:600535
Price:
16.33
CNY
2.06%
Market Closed
Market Cap:
24.4B
CNY
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
18.8
Current
15.1
Median
12.8
Industry
Higher
than median
Higher
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=18.8
Enterprise Value
/
22.7B CNY
EBITDA
1.2B CNY
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
11.7
2-Years Forward
EV/EBITDA
10.8
3-Years Forward
EV/EBITDA
10.1
You don't have any saved screeners yet
